Germany's Ottobock H1 core revenue rises 7.7%, EBITDA margin improves
Germany's Ottobock H1 core revenue rises 7.7%, EBITDA margin improves
Overview
Germany human bionics firm's H1 core revenue rose 7.7% yr/yr to €818.5 mln
Underlying core EBITDA grew 18.1%, with margin up 2.2 percentage points to 25.3%
Company narrowed 2026 guidance for organic core revenue growth and EBITDA margin
Outlook
Ottobock narrows 2026 organic core revenue growth guidance to 6-8% from 5-8%
Company raises 2026 underlying core EBITDA margin forecast to above 27% from above 26.5%
Ottobock expects continued positive momentum in H2 2026 based on first-half performance
Result Drivers
PRODUCT MIX AND ORGANIC GROWTH - Margin improvement attributed to strong organic revenue growth and a favorable product mix, especially in Products & Components (B2B) business
SCALING AND COST CONTROL - Scaling effects, efficiency improvements and disciplined cost control contributed to margin gains
ACQUISITIONS - Revenue growth supported by acquisitions in patient care and expansion of global network
Company press release: ID:nEQ8PsvpWa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Revenue |
| EUR 854.10 mln |
|
H1 Adjusted EBITDA |
| EUR 213.20 mln |
|
H1 Adjusted EBITDA Margin |
| 25.00% |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Ottobock SE & Co KgaA is €81.50, about 38.4% above its August 12 closing price of €58.90
The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 18 three months ago
Reuters Recommended Reads
Aug 12 - Germany's Medios H1 profit hit by pricing pressure; to buy 74% of Caelo to expand API
Aug 11 - Germany's Dermapharm prelim H1 revenue rises, maintains outlook
Aug 12 - Formycon H1 revenue rises sharply on milestone payments, EBITDA loss narrows
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)